Form 4: Syndax Director Podlesak Awarded 48,000 RSUs

Syndax Pharmaceuticals Director Dennis Podlesak was granted 48,000 Restricted Stock Units, increasing his beneficial ownership to 239,763 shares.

Summary

• Dennis Podlesak, a Director of Syndax Pharmaceuticals Inc (SNDX), acquired 48,000 shares of Common Stock.
• The acquisition was an award of Restricted Stock Units (RSUs) with a transaction price of $0 per share.
• The transaction date for this award was February 4, 2026.
• Following this transaction, Dennis Podlesak beneficially owns a total of 239,763 shares directly.
• The RSUs vest one year from the date of grant.
• Shares underlying the RSUs will not be delivered and cannot be transferred or sold until the earlier of separation from service, death, disability, or a change in control.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal. While a routine compensation event, the increase in a director's beneficial ownership through an equity award generally indicates alignment and confidence in the company's long-term performance.

Positives

• The grant of Restricted Stock Units to a director aligns management's interests with those of shareholders, encouraging long-term value creation.
• An increase in insider beneficial ownership can be viewed as a positive signal of confidence in the company's future prospects.

Negatives

• The shares from the RSU award are not immediately liquid and are subject to vesting conditions and delivery restrictions.

Future Outlook

The Restricted Stock Units granted are scheduled to vest one year from the date of grant. The underlying shares will be delivered upon the earlier of separation from service, death, disability, or a change in control.

Industry Context

StockSavvy.ai notes that RSU grants to directors are a common form of equity compensation across the biotechnology and pharmaceutical industries, designed to incentivize long-term commitment and align leadership interests with shareholder returns. This filing reflects a routine compensation event for a director.

Related Party Transactions

• The award of 48,000 Restricted Stock Units to Dennis Podlesak, a Director, constitutes a related party transaction, which is a standard component of director compensation.

Stakeholder Impact

• Shareholders: Increased alignment of a director's financial interests with long-term shareholder value due to equity-based compensation.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• The Restricted Stock Units are expected to vest one year from the grant date of February 4, 2026.

Key Dates

Recommendation

While the RSU grant to a director is a positive signal of alignment and confidence, it is a routine compensation event and not a standalone catalyst for a 'buy' recommendation. It reinforces a 'hold' position for existing investors, indicating stable governance and continued insider commitment.

Keywords

Syndax Pharmaceuticals, SNDX, Restricted Stock Units, RSU, Insider Transaction, Form 4, Director Compensation, Equity Award